Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation

Starling Oncology (NASDAQ: STLN) highlighted recent industry conference participation by its physician leaders and previewed upcoming appearances focused on community oncology.

Rhea-AI Summary

Starling Oncology (NASDAQ: STLN) highlighted recent industry conference participation by its physician leaders and previewed upcoming appearances focused on community oncology.

Jeffrey Langsam participated in Deutsche Bank’s Healthcare Summit on September 17, 2026, and Yale D. Podnos joined the Patient-Centered Oncology Care Conference on September 25. Podnos will join panels on cancer care economics and clinical trial access at the AVBCC Summit on October 8, 2026. He will also present on integrating behavioral health into community oncology at the APG Fall Conference on November 19, 2026.

Key Terms

fee-for-service, utilization management, biosimilar

3 terms

fee-for-service financial

"traditional fee-for-service structure"

A payment model where a provider is paid separately for each test, procedure, visit, or service it delivers, like paying a mechanic for each repair rather than buying a maintenance plan. For investors, it matters because revenue rises with the number and price of services but can be unpredictable and may encourage higher volume over efficiency, affecting profit margins, cash flow stability, and long-term growth prospects.

utilization management technical

"proprietary and innovative Starling Nexus™ utilization management platform"

Utilization management is the process health insurers and providers use to review and approve medical services, tests, and treatments to make sure they are necessary, appropriate, and cost-effective. For investors, it matters because these reviews influence how often care is paid for, affect healthcare providers’ revenues and drug or device sales, and can change costs and demand—like a gatekeeper deciding which requests move forward and which do not.

biosimilar medical

"rising drug costs, IRA-related changes and biosimilar adoption"

A biosimilar is a medicine created to be highly similar to an existing complex drug made from living cells, matching its safety and effectiveness while allowing for small, natural variations. For investors, biosimilars matter because they introduce lower-cost competition when patents end, which can cut prices, shift market share, and change revenue forecasts for companies selling the original drugs, much like a generic version does for simpler chemical medicines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums

CERRITOS, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today highlighted its leadership team’s active season of industry engagement, recapping recent conference participation and previewing upcoming appearances at major industry events.

These presentations reflect Starling Oncology’s role in advancing the science and practice of value-based community oncology. Across these forums, the Company’s physician leaders are sharing clinical insights drawn from its proprietary and innovative Starling Nexus™ utilization management platform and its community-based care model, including approaches to delivering novel therapies at scale, expanding clinical trial access, and integrating behavioral health into cancer care.

“Value-based oncology gives us the opportunity to align clinical innovation with better outcomes for patients. At Starling Oncology, our community-based model allows us to expand access to novel therapies and clinical trials while using evidence-based pathways to deliver high-quality, coordinated cancer care closer to where patients live,” said Yale D. Podnos, M.D., MPH, FACS, Chief Medical Officer and President of Practice of Starling Oncology.

“Community-based oncology practices remain the backbone of cancer care delivery in the United States. Yet practices operating within the traditional fee-for-service structure face increasing pressure from rising drug costs, IRA-related changes and biosimilar adoption. Starling Oncology’s coordinated care model and the recently launched Starling Nexus significantly reduce exposure to these pressures by realigning financial incentives for providers all while maintaining consistent levels of excellence in care,” said Jeffrey Langsam, D.O., Chief Clinical Officer of Starling Oncology.

Recent Presentations

• Deutsche Bank 2026 Healthcare Summit (New York, NY): Jeffrey Langsam, D.O., Chief Clinical Officer, participated in a panel titled “The Future of Oncology” on Thursday, September 17, 2026.
• The American Journal of Managed Care’s Patient-Centered Oncology Care^® (PCOC) Conference (Nashville, TN): Yale D. Podnos, M.D., MPH, FACS, Chief Medical Officer and President of Practice, participated in a panel titled “Cost Plus Capacity: Models for Delivering Novel Therapies at Scale” on Friday, September 25, 2026.

Upcoming Presentations

• Association for Value-Based Cancer Care (AVBCC) 2026 Summit (New York, NY): Dr. Podnos will join two panels on Thursday, October 8, 2026:
  • “New Economics, New Models for the Cancer Care Providers Ecosystem,” 4:00–4:50 p.m. ET
  • “Closing the Clinical Trial Gaps,” 5:00–5:50 p.m. ET
• America’s Physician Groups (APG) Fall Conference 2026 (National Harbor, MD): Dr. Podnos will present “Embedding Behavioral Health in Community Oncology: Measurement-Guided Collaborative Care at Scale” on Thursday, November 19, 2026.

Additional information about the Company’s events is available in the Investor Relations section of the Company’s website at https://investors.starlingoncology.com/.

About Starling Oncology, Inc.

Founded in 2007, Starling Oncology, Inc. (Nasdaq: STLN) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute, Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, Starling Oncology is coordinating cancer care for the better. For more information visit www.starlingoncology.com. Please follow us on LinkedIn, X (formerly Twitter), or Bluesky.

Contacts

Media
ICR Healthcare
StarlingPR@icrhealthcare.com

Investors
ICR Healthcare
StarlingIR@icrhealthcare.com